Patents Examined by Shengjun Wang
  • Patent number: 11324750
    Abstract: Disclosed herein are methods for treating an individual having a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The method may comprise administering a JAK inhibitor, for example ruxolitinib (JAKAFIĀ®), to an individual in need thereof, such individual generally being an individual having, or suspecting of having, SARS-CoV-2 infection. The individual in need thereof may be an individual having, or suspected of having or at risk for developing SARS-CoV-2 infection-related cytokine storm. The individual in need thereof may further be an individual having, or suspected of having SARS-CoV-2 infection-related pneumonia.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 10, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Gang Huang
  • Patent number: 11311547
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: April 26, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard Gendelman, Benson Edagwa
  • Patent number: 11298339
    Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: April 12, 2022
    Assignees: JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC., HEALTHQUEST PHARMA INC.
    Inventors: Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
  • Patent number: 11298344
    Abstract: A composition for inhibiting sodium leakage channel (NALCN), including as an active ingredient N-benzhydryl quinuclidine (NBQN) or a N-benzhydryl quinuclidine derivative represented by the following Formula 1, wherein in the following Formula 1, R is an unsubstituted or substituted benzyl group
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 12, 2022
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Myoung Kyu Park, Hyun Jin Kim, Suyun Hahn, So Woon Kim
  • Patent number: 11285132
    Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 29, 2022
    Assignee: Oncternal Therapeutics, Inc.
    Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
  • Patent number: 11278550
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 22, 2022
    Assignees: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
  • Patent number: 11278534
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 22, 2022
    Assignee: Innovative Molecules GmbG
    Inventors: Gerald Kleymann, Christian Gege
  • Patent number: 11278028
    Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and azadirachtin and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and azadirachtin.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: March 22, 2022
    Assignee: McLaughlin Gormley King Company
    Inventors: Robert A. Suranyi, Donald L. Sundquist
  • Patent number: 11273137
    Abstract: The invention provides methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 15, 2022
    Assignees: Board of Trustees of Michigan State University, Spectrum Health Innovations LLC
    Inventors: Andre Bachmann, Caleb Bupp, Surender Rajasekaran
  • Patent number: 11266658
    Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 8, 2022
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seul Ki Meang, Su-Jun Park, Seong-Shin Kwak
  • Patent number: 11266675
    Abstract: There are disclosed methods of treatment of viral infection. The method makes use of administration of an anti-Hsc70 inhibitor. There are also disclosed uses of anti-Hsc70 inhibitor.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 8, 2022
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventor: Ming-liang He
  • Patent number: 11266647
    Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 8, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Andrew F. Stewart, Peng Wang
  • Patent number: 11266632
    Abstract: Provided are methods of using oleanolic acid and derivatives for treating coronavirus infection. The method includes using propargyl-moiety containing oleanolic acid derivatives for inhibiting coronavirus growth by impairing the viral replication of SARS-CoV-2 through inhibition of the viral function of SARS-CoV-2 main protease.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: March 8, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Raya Soltane, Hani Abdullah Alhadrami, Ahlam Alasiri, Hichem Ben Jannet, Karim Chouaib, Amani Chrouda, Ahmed Mostafa, Rami Adel Pashameah
  • Patent number: 11266644
    Abstract: A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 8, 2022
    Assignee: FUTURE MEDICINE CO., LTD.
    Inventors: Hea Ok Kim, Chong-Woo Park, Mi Ra Yu, Bo Mi Park
  • Patent number: 11261190
    Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 1, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang Liu, Qingyun Ren, Guanghua Yan, Siegfried Goldmann, Yingjun Zhang
  • Patent number: 11253527
    Abstract: The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 22, 2022
    Assignee: ARJIL BIOTECH HOLDING COMPANY LIMITED
    Inventors: Yeh B Wu, Jir-Mehng Lo, Hui Ju Liang, Pei-Hsin Lin, Cheng Huang
  • Patent number: 11254664
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 22, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • Patent number: 11246854
    Abstract: Described are methods of treating or preventing a virus in a subject comprising administering ozonides to the subject.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 15, 2022
    Assignees: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF NEBRASKA MEDICAL CENTER
    Inventors: Ravit Boger, Jonathan Vennerstrom
  • Patent number: 11247998
    Abstract: The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and the use of same as a capsid protein inhibitor, in particular in the prevention and/or treatment of diseases such as hepatitis B, influenza, herpes, AIDS, etc. The definitions of each group in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 15, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Li, Wei He, Yang Chen, Feng He, Weikang Tao
  • Patent number: 11246850
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang